Bill Text: IL HB5420 | 2023-2024 | 103rd General Assembly | Introduced

---

Bill Title: Amends the Newborn Metabolic Screening Act. Provides for the screening and testing of all newborns for Guanidinoacetate Methyltransferase (GAMT) deficiency. Sets forth requirements that must be met before the screening and testing begin. Authorizes the Department of Public Health to implement an additional fee for the screening prior to beginning testing in order to accumulate resources to implement the amendatory Act.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced) 2024-02-09 - Referred to Rules Committee [HB5420 Detail]

Download: Illinois-2023-HB5420-Introduced.html

---

103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB5420 Introduced , by Rep. Kimberly Du Buclet SYNOPSIS AS INTRODUCED:
410 ILCS 240/3.6 new
Amends the Newborn Metabolic Screening Act. Provides for the screening and testing of all newborns for Guanidinoacetate Methyltransferase (GAMT) deficiency. Sets forth requirements that must be met before the screening and testing begin. Authorizes the Department of Public Health to implement an additional fee for the screening prior to beginning testing in order to accumulate resources to implement the amendatory Act.
LRB103 37927 CES 68059 b
A BILL FOR
HB5420 LRB103 37927 CES 68059 b
AN ACT concerning health.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 5. The Newborn Metabolic Screening Act is amended
by adding Section 3.6 as follows:
(410 ILCS 240/3.6 new)
Sec. 3.6. Guanidinoacetate Methyltransferase (GAMT)
deficiency.
(a) In accordance with the timetable specified in this
Section, the Department shall provide all newborns with
screening tests for the presence of Guanidinoacetate
Methyltransferase (GAMT) deficiency. The testing shall begin
within 12 months after the occurrence of all of the following:
(1) the establishment and verification of relevant and
appropriate performance specifications as defined under
the federal Clinical Laboratory Improvement Amendments and
regulations thereunder for Federal Drug
Administration-cleared or in-house developed methods,
performed under an institutional review board approved
protocol, if required;
(2) the availability of quality assurance testing and
comparative threshold values for GAMT;
(3) the acquisition and installment by the Department

HB5420 - 2 - LRB103 37927 CES 68059 b